Form 4: Dyne Therapeutics CEO John Cox Reports Share Purchase, Gifts, and Section 16(b) Compliance Payment

Dyne Therapeutics CEO John Cox reported a significant share purchase, subsequent gifts to family trusts, and a payment to the company to resolve a short-swing profit violation under Section 16(b) of the Exchange Act.

Summary

• John Cox, CEO & President and Director of Dyne Therapeutics, Inc. (DYN), acquired 100,000 shares of common stock on July 14, 2025, at a weighted average price of $9.11 per share.
• Following this purchase, his direct beneficial ownership increased to 242,179 shares.
• On July 15, 2025, Mr. Cox gifted a total of 40,000 shares (four separate gifts of 10,000 shares each) from his direct holdings to four trusts established for the benefit of his child.
• As a result of these gifts, his direct beneficial ownership decreased to 202,179 shares, while 72,000 shares are now held indirectly through these trusts (18,000 shares per trust).
• The purchase of 100,000 shares was found to be matchable under Section 16(b) of the Securities Exchange Act of 1934 to the extent of 8,121 shares.
• This short-swing transaction was matched with sales of 4,061 shares on March 5, 2025, and 4,060 shares on June 5, 2025, which were executed to satisfy tax withholding obligations related to the vesting of restricted stock units granted on December 4, 2024.
• Mr. Cox has paid an aggregate amount of $29,017.22 to Dyne Therapeutics, Inc., representing the deemed profit realized from the Section 16(b) short-swing transaction.
• His total beneficial ownership after all reported transactions is 274,179 shares, which includes 127,138 unvested Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The acquisition of 100,000 shares by the CEO is a positive signal of confidence. However, the disclosure of a Section 16(b) short-swing profit violation, even though resolved with a payment, introduces a negative element related to compliance oversight. The gifts to trusts are neutral from a company performance perspective.

Positives

• CEO John Cox acquired 100,000 shares of Dyne Therapeutics common stock, indicating a significant personal investment and potential confidence in the company's future.
• The prompt resolution and payment of $29,017.22 for the Section 16(b) short-swing profit violation demonstrates compliance and good corporate governance by the reporting person.

Negatives

• The reporting person, CEO John Cox, engaged in a short-swing transaction that resulted in a Section 16(b) violation, requiring a payment of $29,017.22 to the company.
• The gifting of 40,000 shares to family trusts reduces the CEO's direct ownership stake in the company.

Risks

• Potential for future Section 16(b) violations if transactions are not carefully managed, which could lead to reputational damage or further financial penalties for the reporting person.

Future Outlook

The document does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on insider trading activities.

Management Comments

• The Reporting Person's purchase of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), to the extent of 8,121 shares, with the Reporting Person's sale of 4,061 shares on March 5, 2025 and 4,060 shares on June 5, 2025 automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024.
• The Reporting Person has paid to the Issuer an aggregate amount of $29,017.22, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act.
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
• This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person.

Industry Context

This Form 4 filing details insider transactions by a key executive at Dyne Therapeutics, a biotechnology company. While the specific transactions are internal to the company's executive, the overall trend of insider buying or selling can provide insights into management's confidence in the biotech sector, which is often characterized by high R&D costs, regulatory hurdles, and significant market volatility. The Section 16(b) compliance highlights the strict regulatory environment governing insider trading in the U.S. financial markets.

Comparison to Industry Standards

• The purchase of shares by a CEO is generally viewed positively, aligning management's interests with shareholders. While specific comparable companies are not mentioned, insider buying is a common signal across all industries, including biotech.
• The Section 16(b) violation, while resolved, indicates a lapse in compliance with insider trading rules. While such violations are not unique to the biotech industry, they underscore the importance of robust internal controls and legal counsel for executives in all publicly traded companies, similar to those at peers like Sarepta Therapeutics or Alnylam Pharmaceuticals, which also operate in the rare disease/genetic medicine space.
• Gifting shares to family trusts is a common estate planning strategy for high-net-worth individuals across industries and does not inherently reflect on the company's performance or industry standards.

Corporate Governance

Legal Proceedings

• The document details a Section 16(b) short-swing profit violation by the CEO, which is a regulatory compliance matter under the Securities Exchange Act of 1934. This was resolved by the CEO paying $29,017.22 to the Issuer.

Related Party Transactions

• Gifts of 40,000 shares of common stock by the CEO to four separate trusts established for the benefit of his child.

Stakeholder Impact

• Shareholders: The CEO's purchase of 100,000 shares could be seen as a positive signal of confidence, potentially influencing investor sentiment. The Section 16(b) violation, while resolved, highlights compliance risks that could concern some investors, though the payment to the company mitigates the financial impact.
• Management/Executives: The CEO's compliance issue serves as a reminder of the strict regulatory environment for insider transactions and the importance of careful planning to avoid short-swing profit violations.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request from the Issuer, any security holder, or the SEC staff.

Key Dates

Recommendation

Keywords

Dyne Therapeutics, DYN, SEC Form 4, Insider Trading, John Cox, CEO, Share Purchase, Stock Gifts, Section 16(b), Short-Swing Profit, Beneficial Ownership, Corporate Governance, Restricted Stock Units, RSUs